| Bioactivity | Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes[1]. |
| CAS | 144412-50-0 |
| Formula | C26H29F3N4O8 |
| Molar Mass | 582.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Moliterno DJ, et al. Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombolysis. 1995;2(3):165-169. |
Lamifiban TFA
CAS: 144412-50-0 F: C26H29F3N4O8 W: 582.53
Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.